Partner With Us NRI

Company details

6M Return -
1Y Return -
Mkt Cap.(Cr) -
Volume -
Div Yield -
OI Chg %
Volume -

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





No Data Found
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found


  • About Company
  • Company Info
  • Listing Info
  • ABL Bio Technologies Limited (ABL) is an India-based biotechnology company. The Company operates in three segments: formulation, research and development and the Docosahexaenoic acid (DHA) project. The Company focuses on discovery, collection of microbes, establishment of compound libraries, discovery of drug and nutrition targets and conducting research and converting the strains/compounds in to deliverable active pharmaceutical products. ABL Biotechnologies was incorporated in the year 1992. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates. Companys R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India. Companys microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms. Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India. Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states. ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture. As of March 31, 2010, the Company is conducting research on multiple Active Pharmaceutical Ingredients (APIs).

Read More

Registered Address

No 1 Wallers Lane 1st Floor, Room 3 Mataji Complex Mount Rd, Chennai, Tamil Nadu, 600002

Website : http://www.ablbiotechnologies.com


Cameo Corporate Services Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 526955
NSE Code :
Book Closure Date (Month) : Sep
BSE Group : Z
ISIN : INE707D01016

ICICIdirect ABL Bio-Technologies Ltd FAQ

You can buy ABL Bio-Technologies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy ABL Bio-Technologies Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of the closing price of ABL Bio-Technologies Ltd was ₹ -.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of , the market cap of ABL Bio-Technologies Ltd stood at ₹ 0.00.
The latest PE ratio of ABL Bio-Technologies Ltd as of is 0
The latest PB ratio of ABL Bio-Technologies Ltd as of is 0
The 52-week high of ABL Bio-Technologies Ltd is ₹ 0 while the 52-week low is ₹ 0 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote